## HOLX: Hologic, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.2% below STRENGTH zone (3.0-6.0%); PEG 1.65 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.21)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 1, Bearish: 1)

**1. Hologic says 2026 CVR is more challenging with stopped shipment of product**
- Source: MSN | 20260103T180758 | Bearish | Relevance: 100%
- Hologic stated that achieving its 2026 CVR (Contingent Value Right) targets has become more challenging due to the halted shipment of a product. This development suggests potential financial implications for the company related to its product delivery and revenue projections.

**2. Hologic Trading Near 52-Week High: How Should You Play the Stock?**
- Source: Finviz | 20260105T135404 | Bullish | Relevance: 97%
- Hologic's shares closed near their 52-week high, outperforming its industry and sector, driven by strong growth in Molecular Diagnostics, Breast Health, and GYN Surgical divisions, alongside a proposed $18.3 billion take-private deal. Despite macroeconomic headwinds and tariffs, the company's innovation, clinical evidence, and regulatory approvals suggest a "hold" position for current investors due to its favorable price performance and appealing valuation. Prospective buyers are advised to wait for more clarity.

**3. Capital One Financial stock hits all-time high at $249.78 USD**
- Source: Investing.com Canada | 20260105T150809 | Neutral | Relevance: 62%
- Capital One Financial (COF) stock has reached an all-time high of $249.78 USD, reflecting a 36.52% increase over the past year. This milestone highlights investor confidence and the company's strong market position, further bolstered by positive analyst evaluations and price target increases from firms like BTIG, BofA Securities, and Wolfe Research. Goldman Sachs, however, removed Capital One Financial from its US Conviction List.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | Evercore ISI Gr | $78 | $79 | -1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | Evercore ISI Gr | down | In-Line |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 15 ($0.00M) |
| Sells | 26 ($6.64M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-2.2%)
- T. Rowe Price Invest: 9.7% (-10.5%)
- Blackrock Inc.: 8.7% (-2.7%)
- Manufacturers Life I: 4.7% (-5.2%)
- State Street Corpora: 4.5% (-1.2%)

### Key Risks

1. Insider selling cluster: $6.6M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- New product launch cycle could drive revenue acceleration.
- Momentum building: MRS_10 improving +1.5% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.65 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (3.8x). Analyst sentiment negative (1 target cuts vs 0 raises). Insider selling cluster ($6.6M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 8 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.7B |
| Beta | 0.70 |
| 52W Range | $51.90 - $75.34 |
| Short Interest | 2.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.65 |
| Forward P/E | 15.0 |
| Current P/E | 16.4 |
| YoY Growth | 9.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.2% to 0.2% (+1.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.8pp (needs >3.0% for momentum thesis). MRS_5 at 0.1% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.13x) but short-term weakness (below SMA20). RSI neutral at 57. OFD pattern: +MUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.25% (CS: 44) | Neutral |
| RSI_14 | 56.7 | Neutral |
| MACD Histogram | -0.10 | Bearish |
| vs SMA20 | 0.999x | Below |
| vs SMA50 | 1.003x | Above |
| vs SMA200 | 1.126x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $74.75
- **Stop Loss:** $74.21 (0.7% risk)
- **Target:** $75.29 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1597
- **Position Value:** $119,375.75
- **Portfolio %:** 119.38%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-04 (Est: $1.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.10 | $1.13 | +2.7% |
| 2025Q2 | $1.05 | $1.08 | +2.7% |
| 2025Q1 | $1.02 | $1.03 | +1.4% |
| 2024Q4 | $1.02 | $1.03 | +1.4% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_10*